These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22157006)

  • 1. Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.
    Sevrioukova IF; Poulos TL
    J Biol Chem; 2012 Jan; 287(5):3510-7. PubMed ID: 22157006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
    Sevrioukova IF; Poulos TL
    Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of CYP3A4 with caffeine: First insights into multiple substrate binding.
    Sevrioukova IF
    J Biol Chem; 2023 Sep; 299(9):105117. PubMed ID: 37524132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4.
    Sevrioukova IF; Poulos TL
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):486-491. PubMed ID: 28031486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Site of Metabolism (SOM) Prediction of Ligand for CYP3A4 Enzyme: Comparison of Glide XP and Induced Fit Docking (IFD).
    Lokwani DK; Sarkate AP; Karnik KS; Nikalje APG; Seijas JA
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32244772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir.
    Sevrioukova IF
    Arch Biochem Biophys; 2024 Aug; 758():110071. PubMed ID: 38909836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining CYP3A4 structural responses to substrate binding. Raman spectroscopic studies of a nanodisc-incorporated mammalian cytochrome P450.
    Mak PJ; Denisov IG; Grinkova YV; Sligar SG; Kincaid JR
    J Am Chem Soc; 2011 Feb; 133(5):1357-66. PubMed ID: 21207936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules.
    Sevrioukova I
    Biochemistry; 2019 Feb; 58(7):930-939. PubMed ID: 30676743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
    Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
    J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4.
    Sevrioukova IF
    Biochemistry; 2017 Jun; 56(24):3058-3067. PubMed ID: 28590129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket.
    Ohkura K; Kawaguchi Y; Watanabe Y; Masubuchi Y; Shinohara Y; Hori H
    Anticancer Res; 2009 Mar; 29(3):935-42. PubMed ID: 19414330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of human cytochrome P4503A4 with ritonavir analogs.
    Sevrioukova IF; Poulos TL
    Arch Biochem Biophys; 2012 Apr; 520(2):108-16. PubMed ID: 22410611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7.
    Sevrioukova IF
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity.
    Moore CD; Shahrokh K; Sontum SF; Cheatham TE; Yost GS
    Biochemistry; 2010 Oct; 49(41):9011-9. PubMed ID: 20812728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4.
    Nair PC; McKinnon RA; Miners JO
    Drug Metab Dispos; 2019 Jun; 47(6):616-631. PubMed ID: 30902802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer.
    Denisov IG; Grinkova YV; Baylon JL; Tajkhorshid E; Sligar SG
    Biochemistry; 2015 Apr; 54(13):2227-39. PubMed ID: 25777547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
    Bonn B; Masimirembwa CM; Castagnoli N
    Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of binding modes of ligands to multiple conformations of CYP3A4.
    Teixeira VH; Ribeiro V; Martel PJ
    Biochim Biophys Acta; 2010 Oct; 1804(10):2036-45. PubMed ID: 20601222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen.
    Shahrokh K; Cheatham TE; Yost GS
    Biochim Biophys Acta; 2012 Oct; 1820(10):1605-17. PubMed ID: 22677141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane Interactions, Ligand-Dependent Dynamics, and Stability of Cytochrome P4503A4 in Lipid Nanodiscs.
    Treuheit NA; Redhair M; Kwon H; McClary WD; Guttman M; Sumida JP; Atkins WM
    Biochemistry; 2016 Feb; 55(7):1058-69. PubMed ID: 26814638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.